Ultimo aggiornamento :
03/05/2024
Antibiotico   Doxycycline hyclate  
Iniezione
Stabilità in soluzione Stabilità in miscela Fattori che influenzano la stabilità Compatibilità Metodo di iniezione Bibliografia Pdf
   Struttura chimica  

Nome commerciale   Nome commerciale     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Doximycin Finlandia
Doxy Nuova Zelanda, Stati Uniti d’America
Doxycyclin Lussemburgo
Doxycycline Stati Uniti d’America
Doxycyclinum Polonia
Doxyferm Svezia
Doxyhexal Germania, Lussemburgo
Doxylin Norvegia
Doxymycin Finlandia
Vibramycin Paesi Bassi, Stati Uniti d’America
Vibraveineuse Francia, Marocco, Svizzera
Vibravenös Austria, Svizzera
Vibravenosa Colombia, Spagna
Vibravenous Emirati Arabi Uniti
Zadorin Svizzera
Bibliografia   Iniezione   Bibliografia : Doxycycline hyclate  
Tipo Pubblicazione
3 Rivista Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
59 Rivista Trissel LA, Gilbert DL, Martinez JF, Kim MC.
Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
81 Rivista Trissel LA, Martinez JF.
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 672-678.
84 Rivista Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499.
99 Rivista Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
182 Rivista Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60.
198 Rivista Gayed AA, Kheshary PR, Hinkle RL.
Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection.
Am J Health-Syst Pharm 1995 ; 52: 516-520.
244 Rivista Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913.
249 Rivista Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
266 Rivista Patel PR.
Compatibility of meropenem with commonly used injectable drugs.
Am J Health-Syst Pharm 1996 ; 53: 2853-2855.
299 Rivista Trissel LA, Martinez JF, Gilbert DL.
Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300 Rivista Trissel LA, Gilbert DL, Martinez JF.
Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301 Rivista Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM.
Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307 Rivista Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799.
317 Rivista Kershaw BP, Monnier HL, Mason JH.
Visual compatibility of premixed theophylline or heparin with selected drugs for IV administration.
Am J Hosp Pharm 1993 ; 50: 1360-1362.
334 Rivista Trissel LA, Tramonte SM, Grilley BJ.
Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 988-992.
335 Rivista Trissel LA, Bready BB, Kwan JW, Santiago NM.
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 402-406.
336 Rivista Forman JK, Lachs JR, Souney PF.
Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection.
Am J Hosp Pharm 1987 ; 44: 1408-1409.
385 Rivista Benedict MK, Roche VF, Banakar UV, Hilleman DE.
Visual compatibility of amiodarone hydrochloride with various antimicrobial agents during simulated Y-site injection.
Am J Hosp Pharm 1988 ; 45: 1117-1118.
405 Rivista Nieves-Cordero AL, Luciw HM, Souney PF.
Compatibility of narcotic analgesic solutions with various antibiotics during simulated Y-site injection.
Am J Hosp Pharm 1985 ; 42: 1108-1109.
465 Rivista Wohlford JG, Wright JC, Wilson MR.
More information on the visual compatibility of hetastarch with injectable critical-care drugs.
Am J Hosp Pharm 1990 ; 47: 297-298.
472 Rivista Wohlford JG, Fowler MD.
Visual compatibility of hetastarch with injectable critical-care drugs.
Am J Hosp Pharm 1989 ; 46: 995-996.
479 Rivista Min DI, Brown T, HWang GC.
Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 2964-2966.
492 Rivista Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189.
563 Rivista Petrick RJ, Wolleben JE, Vargas TA.
Stability of frozen solutions of doxycycline hyclate for injection.
Am J Hosp Pharm 1978 ; 35: 1386-1387.
905 Rivista Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017.
999 Rivista Watson D.
Piggyback compatibility of antibiotics with pediatric parenteral nutrition solution.
JPEN 1985 ; 9: 220-224.
1047 Rivista Souney PF, Colucci RD, Mariani G, Campbell D.
Compatibility of magnesium sulfate solutions with various antibiotics during simulated Y-site injection.
Am J Hosp Pharm 1984 ; 41: 323-324.
1410 Rivista Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145.
1415 Rivista Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M.
Compatibility of medications with 3-in-1 parenteral nutrition admixtures.
JPEN 1999 ; 23: 67-74.
1423 Rivista Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518.
1664 Rivista King AD, Stewart JT, Warren FW.
Stability of cefmetazole-doxycycline mixtures in sodium chloride and dextrose injections.
J Clin Pharm Ther 1994 ; 19: 317-325.
1712 Rivista Trissel LA, Saenz CA.
Compatibility screening of Precedex during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 230-233.
1713 Rivista Trissel LA, Saenz CA.
Compatibility screening of bivalirudin during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 311-315.
1721 Rivista Trissel LA, Williams KY, Baker MB.
Compatibility screening of Hextend during simulated Y-site administration with other drugs.
Int J Pharm Compound 2001 ; 5: 69-72.
1754 Rivista Trissel LA, Gilbert DL, Wolkin AC.
Compatibility of docetaxel with selected drugs during simulated Y-site administration.
Int J Pharm Compound 1999 ; 3: 241-244.
1803 Rivista Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB.
Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2003 ; 60: 80-85.
1925 Rivista Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519.
1953 Rivista Trissel LA, Saenz CA, Ogundele AB, Ingram DS.
Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
3128 Laboratorio Mitomycine (Amétycine®) - Résumé Caractéristiques du Produit
Prostrakan 2013
3254 Rivista Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L.
Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration
Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3531 Laboratorio Morphine sulphate 10 mg/mL injection BP – Summary of Product Characteristics
Wockhardt 2014
3644 Laboratorio Calcium gluconate® - Summary of Product Characteristics
Hameln Pharmaceuticals 2010
3674 Laboratorio Erythromycin lactobionate - Summary of Product Characteristics
PanPharma 2016
3791 Poster Sadou Yaye H, Burtet E, Hamel C, Aljhni R, Gard C, Tilleul P.
Étude de la compatibilité physico-chimique du phloroglucinol injectable durant les mélanges au sein des tubulures en Y.
Apifh Congress, Paris November 2014 2014
3827 Poster Ghazi I.M, Hamada Y, Nicolau D.P.
Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions.
ASHP Midyear 2015
3828 Poster Thabit A.K, Hamada Y, Nicolau D.P.
Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.
ASHP Midyear 2015
3829 Poster So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.
Compatibility of isavunazonium sulfate during simulated Y-site administration.
ASHP Midyear 2015
4055 Rivista Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.
Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145 Rivista Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P.
Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4471 Laboratorio Amétycine 10 mg poudre pour solution injectable - Résumé des caractéristiques du produit - Oct 10, 2019
Kyowa Kirin Pharma 2019
4528 Rivista Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N.
Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration.
Int J Pharm Compound 2021 ;25,1:52-61

  Mentions Légales